A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.

Condition or disease

Intervention/treatment

Phase

AIDS Dementia ComplexHIV Infections

Drug: Abacavir sulfate

Phase 3

Detailed Description:

Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry and will then be stratified depending on whether their regimen contains zidovudine (ZDV). Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 65 Years (Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria

Patients must have:

Documented HIV infection.

Evidence of HIV - associated dementia.

Been on stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

Debilitated as a result of their HIV disease, associated illness or therapies who the investigator determines will not be able to complete the 12 week randomized dosing period.

Memorial Sloan-Kettering (MSK) score of >= 3 for dementia.

Confounding neurological diseases which may interfere with interpretation of neurological and neurophysical assessments.

Malabsorption syndrome or other gastrointestinal dysfunction which renders them unable to take oral medication.

Chronic diseases such as diabetes, congestive heart failure, cardiomyopathy, other cardiac dysfunctions, etc., which in the investigator's opinion would compromise the safety of the patient.

Treatment with cytotoxic chemotherapeutic agents within the first 12 weeks of the study.

Treatment with nerve growth factor within the first 12 weeks of study.

The use of narcotic analgesics, sedatives, benzodiazepines, antidepressants, anti-psychotic agents and other psychoactive drugs which would interfere with the assessment of the neurological and neurophysical status of the patient.

Use of stavudine (d4T) during the first 12 weeks of the study.

Immunomodulating agents (except GM/G-CSF or epoietin).

Psychoactive drugs (at the investigator's discretion).

Concurrent Treatment:

Excluded:

Treatment with radiation therapy within the first 12 weeks of the study.

NOTE:

With the exception of local treatment for Kaposi's sarcoma.

Patients with any of the following prior conditions are excluded:

Previous neurological disease unrelated to HIV infection.

History of clinically apparent hepatitis within the last 6 months.

History of clinically apparent pancreatitis in the last 6 months.

Prior Medication:

Excluded:

Treatment with cytotoxic chemotherapeutic agents within 1 month of entry.

Participation in investigational antiretroviral trials within the past 3 months.